Inhibrx (INBX) News Today → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free INBX Stock Alerts $34.29 -0.40 (-1.15%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Offfinance.yahoo.com - May 10 at 6:47 PMInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Offprnewswire.com - May 10 at 6:36 PMINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXbusinesswire.com - May 9 at 3:36 PMInhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Mergerprnewswire.com - May 8 at 4:37 PMRussell Investments Group Ltd. Decreases Stock Position in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - May 4 at 5:57 AMAs more rare disease therapies launch, their prices are risingmsn.com - April 16 at 2:33 PMInhibrx (NASDAQ:INBX) Sees Unusually-High Trading Volumemarketbeat.com - April 8 at 3:24 PMInhibrx, Inc. (NASDAQ:INBX) Short Interest Down 17.9% in Marchmarketbeat.com - March 30 at 8:18 PMInhibrx, Inc. (NASDAQ:INBX) Shares Acquired by Wellington Management Group LLPmarketbeat.com - March 28 at 4:07 AMInhibrx, Inc. (NASDAQ:INBX) Sees Significant Drop in Short Interestmarketbeat.com - March 18 at 5:15 PMINBX Apr 2024 50.000 putfinance.yahoo.com - March 16 at 10:41 AMINBX Apr 2024 55.000 callfinance.yahoo.com - March 16 at 10:41 AMRA Capital Management L.P. Purchases 870,340 Shares of Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - March 6 at 2:35 PMFmr LLC Trims Stake in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - March 4 at 5:02 AMShort Interest in Inhibrx, Inc. (NASDAQ:INBX) Drops By 12.5%marketbeat.com - March 4 at 12:34 AMEventide Asset Management LLC Purchases New Stake in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - March 1 at 9:33 AMInhibrx just downgraded at Jefferies, here's whyrealmoney.thestreet.com - February 29 at 10:36 AMInhibrx, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Resultsfinanznachrichten.de - February 28 at 1:23 PMInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Resultsprnewswire.com - February 28 at 9:15 AMInhibrx, Inc. (NASDAQ:INBX) Shares Sold by Rafferty Asset Management LLCmarketbeat.com - February 22 at 6:20 AMLoomis Sayles & Co. L P Has $20.49 Million Stock Holdings in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - February 16 at 8:00 AMINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXbusinesswire.com - February 10 at 11:09 AMINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXbusinesswire.com - February 10 at 10:46 AMInhibrx, Inc. (NASDAQ:INBX) Short Interest Up 20.3% in Januarymarketbeat.com - January 28 at 10:20 PMLifesci Capital Downgrades Inhibrx (NASDAQ:INBX) to Market Performmarketbeat.com - January 25 at 6:42 AMSanofi signs agreement to acquire Inhibrx for $1.7bnmsn.com - January 24 at 2:06 PMBiotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & Morefinance.yahoo.com - January 24 at 2:06 PMSanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisitionseekingalpha.com - January 24 at 9:00 AMInhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?finance.yahoo.com - January 24 at 8:58 AMInhibrx just downgraded at LifeSci Capital, here's whyrealmoney.thestreet.com - January 24 at 3:57 AMThese Stocks Are Moving the Most Today: United, Logitech, Archer Daniels, Inhibrx, J&J, Netflix, and Moremsn.com - January 23 at 10:22 AMSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Updatemarketwatch.com - January 23 at 10:22 AMFrance's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 blnreuters.com - January 23 at 10:22 AMINBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholderstmcnet.com - January 23 at 10:22 AMJMP Securities Reaffirms "Market Perform" Rating for Inhibrx (NASDAQ:INBX)marketbeat.com - January 23 at 8:23 AMInhibrx Inc Ordinary Shares INBXmorningstar.com - December 9 at 12:42 PMInhibrx Inc Ordinary Sharesmorningstar.com - December 2 at 12:50 PMInhibrx posts Q3 resultsmsn.com - November 10 at 1:16 PMInhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - November 10 at 8:16 AMInhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - November 9 at 8:10 PMInhibrx reports initial Phase I Ewing sarcoma trial datamsn.com - November 4 at 7:27 AMInhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcomafinance.yahoo.com - November 2 at 1:13 PMInhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canadafinance.yahoo.com - September 19 at 6:29 PMCitigroup Inc. Buys 37,822 Shares of Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - September 6 at 4:41 AMInhibrx Shares Rise 15% After Private Placement Financingmarketwatch.com - August 29 at 3:34 PMInhibrx Announces $200 Million Private Placement Financingfinance.yahoo.com - August 29 at 10:09 AMJMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Knowmarkets.businessinsider.com - August 23 at 4:06 PMJMP Securities Maintains Inhibrx (INBX) Outperform Recommendationnasdaq.com - August 23 at 9:45 AMJMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)markets.businessinsider.com - August 23 at 4:45 AMInhibrx, Inc. (NASDAQ:INBX) Shares Sold by Barclays PLCmarketbeat.com - August 21 at 4:35 AM Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now INBX Media Mentions By Week INBX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INBX News Sentiment▼0.540.52▲Average Medical News Sentiment INBX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INBX Articles This Week▼61▲INBX Articles Average Week Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fusion Pharmaceuticals News Beam Therapeutics News ADMA Biologics News Ginkgo Bioworks News Neumora Therapeutics News Recursion Pharmaceuticals News Tarsus Pharmaceuticals News Sana Biotechnology News 4D Molecular Therapeutics News Apogee Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INBX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
